Trials / Completed
CompletedNCT01629758
Safety Study of IL-21/Anti-PD-1 Combination in the Treatment of Solid Tumors
A Phase 1 Dose Escalation Study of BMS-982470 (Recombinant Interleukin-21, rIL-21) in Combination With BMS-936558 (Anti-PD-1) in Subjects With Advanced or Metastatic Solid Tumors
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 33 (actual)
- Sponsor
- Bristol-Myers Squibb · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine whether the combination of the 2 drugs being investigated (IL-21 and anti-PD-1) is safe, and provide preliminary information on the clinical benefits of two different schedules of the combination.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Denenicokin | |
| BIOLOGICAL | Nivolumab |
Timeline
- Start date
- 2012-06-01
- Primary completion
- 2014-12-01
- Completion
- 2014-12-01
- First posted
- 2012-06-28
- Last updated
- 2015-03-06
Locations
5 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT01629758. Inclusion in this directory is not an endorsement.